HUP0402303A2 - Módosított VII-es faktor polipeptidek folyékony készítménye - Google Patents

Módosított VII-es faktor polipeptidek folyékony készítménye

Info

Publication number
HUP0402303A2
HUP0402303A2 HU0402303A HUP0402303A HUP0402303A2 HU P0402303 A2 HUP0402303 A2 HU P0402303A2 HU 0402303 A HU0402303 A HU 0402303A HU P0402303 A HUP0402303 A HU P0402303A HU P0402303 A2 HUP0402303 A2 HU P0402303A2
Authority
HU
Hungary
Prior art keywords
factor vii
modified factor
liquid composition
vii polypeptides
formulation
Prior art date
Application number
HU0402303A
Other languages
English (en)
Inventor
Birthe Lykkegaard Hansen
Michael Bech Jensen
Troels Kornfelt
Original Assignee
Novo Nordisk A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk A/S filed Critical Novo Nordisk A/S
Publication of HUP0402303A2 publication Critical patent/HUP0402303A2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

A jelen találmány folyékony, vizes készítménnyel kapcsolatos, ahol akészítmény (i) egy módosított VII-faktor polipeptidet, (ii) egy a pH-értéket a körülbelül 4,0-8,0 pH-tartományban tartani képes anyagot,(iii) egy antioxidánst, és (iv) kalciumsót, vagy magnéziumsót, vagyezek keverékét tartalmazza. Ó
HU0402303A 2001-12-21 2002-12-20 Módosított VII-es faktor polipeptidek folyékony készítménye HUP0402303A2 (hu)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA200101949 2001-12-21
DKPA200101948 2001-12-21
US34688802P 2002-01-07 2002-01-07
US34639902P 2002-01-07 2002-01-07
PCT/DK2002/000894 WO2003055511A1 (en) 2001-12-21 2002-12-20 Liquid composition of modified factor vii polypeptides

Publications (1)

Publication Number Publication Date
HUP0402303A2 true HUP0402303A2 (hu) 2005-01-28

Family

ID=27439852

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0402303A HUP0402303A2 (hu) 2001-12-21 2002-12-20 Módosított VII-es faktor polipeptidek folyékony készítménye

Country Status (12)

Country Link
US (1) US20040043933A1 (hu)
EP (1) EP1458407A1 (hu)
JP (1) JP2005530682A (hu)
CN (1) CN1606452A (hu)
AU (1) AU2002351755A1 (hu)
BR (1) BR0215218A (hu)
CA (1) CA2470313A1 (hu)
HU (1) HUP0402303A2 (hu)
IL (1) IL162618A0 (hu)
PL (1) PL370656A1 (hu)
RU (1) RU2004122430A (hu)
WO (1) WO2003055511A1 (hu)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0304050A3 (en) * 2001-05-02 2005-12-28 Novo Nordisk As Modified fvii in treatment of ards
KR20040065278A (ko) * 2001-12-21 2004-07-21 노보 노르디스크 에이/에스 변경된 인자 ⅶ 폴리펩티드의 액체 조성물
AU2002351756A1 (en) 2001-12-21 2003-07-15 Novo Nordisk Health Care Ag Liquid composition of factor vii polypeptides
US20040009918A1 (en) * 2002-05-03 2004-01-15 Hanne Nedergaard Stabilised solid compositions of modified factor VII
CA2490342C (en) 2002-06-21 2015-06-16 Novo Nordisk A/S Stabilised solid compositions of factor vii polypeptides
MXPA05009914A (es) * 2003-03-18 2006-01-09 Novo Nordisk Healthcare Ag Composiciones farmaceuticas acuosas, liquidas de polipeptidos del factor vii.
US7897734B2 (en) * 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
CA2525224A1 (en) * 2003-05-23 2004-12-02 Michael Bech Jensen Protein stabilization in solution
EP1641487B1 (en) 2003-06-25 2012-02-29 Novo Nordisk Health Care AG Liquid composition of factor vii polypeptides
DE602004023848D1 (de) * 2003-07-01 2009-12-10 Novo Nordisk Healthcare Ag Von factor vii polypeptiden
BRPI0413518A (pt) 2003-08-14 2006-10-10 Novo Nordisk Healthcare Ag composição farmacêutica lìquida aquosa, método para preparar e uso da mesma, método para tratar uma sìndrome responsiva ao fator vii, e, recipiente hermético
WO2005023308A1 (en) * 2003-09-05 2005-03-17 Maxygen Holdings Ltd. Formulations of vitamin k-dependent polypeptides and sulfoalkyl ether cycloextrins
DK2298287T3 (en) * 2003-12-19 2018-07-23 Novo Nordisk Healthcare Ag Stabilized compositions of factor VII polypeptides
ES2717248T3 (es) 2004-04-23 2019-06-20 Cydex Pharmaceuticals Inc Formulación de DPI que contiene sulfoalquil éter ciclodextrina
MXPA06012676A (es) 2004-05-04 2007-04-02 Novo Nordisk Healthcare Ag Glucoformas o-enlazadas de polipeptidos y metodos de fabricacion de los mismos.
US7148067B2 (en) * 2004-08-31 2006-12-12 The Board Of Trustees Of The University Of Illinois Thromboplastin reagents
JP2006137678A (ja) * 2004-11-10 2006-06-01 Shionogi & Co Ltd インターロイキン−２組成物
JP2008530208A (ja) * 2005-02-16 2008-08-07 ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ 万能前凝固薬
EP1869082B1 (en) * 2005-03-04 2011-04-13 The Board Of Trustees Of The University Of Illinois Coagulation and fibrinolytic cascades modulator
US7629331B2 (en) 2005-10-26 2009-12-08 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
WO2008127702A2 (en) * 2007-04-13 2008-10-23 Catalyst Biosciences, Inc. Modified factor vii polypetides and uses thereof
WO2009046194A2 (en) * 2007-10-05 2009-04-09 The Board Of Trustees Of The University Of Illinois Fibrin sealant
US20100297257A1 (en) 2007-11-09 2010-11-25 National Institutes Of Health (Nih), U.S. Dept. Of Health And Human Services (Dhhs) Anticoagulant antagonist and hemophillia procoagulant
TWI465247B (zh) 2008-04-11 2014-12-21 Catalyst Biosciences Inc 經修飾的因子ｖｉｉ多肽和其用途
GEP20156209B (en) * 2008-08-15 2015-01-12 Aironvud Farmasiutikalz Ink Linaclotide-containing formulations for oral administration
CA2770077A1 (en) * 2009-08-06 2011-02-10 Ironwood Pharmaceuticals, Inc. Formulations comprising linaclotide
ES2638589T3 (es) 2010-02-17 2017-10-23 Ironwood Pharmaceuticals, Inc. Tratamientos para trastornos intestinales
ES2763404T3 (es) 2010-08-11 2020-05-28 Ironwood Pharmaceuticals Inc Formulaciones estables de linaclotida
US9708371B2 (en) 2011-08-17 2017-07-18 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
CN105142656B (zh) 2013-03-12 2019-05-10 大日本住友制药株式会社 水性液体组合物
CN107490676B (zh) * 2017-08-10 2019-02-12 迈克生物股份有限公司 一种补体c3检测试剂盒及检测方法
CN107356764A (zh) * 2017-08-10 2017-11-17 迈克生物股份有限公司 一种载脂蛋白e检测试剂盒及检测方法
CN107490696A (zh) * 2017-08-10 2017-12-19 迈克生物股份有限公司 一种视黄醇结合蛋白检测试剂盒及检测方法
CN107490675B (zh) * 2017-08-10 2019-02-12 迈克生物股份有限公司 一种免疫比浊试剂盒及检测方法
EP3833381B1 (en) 2019-08-15 2022-08-03 Catalyst Biosciences, Inc. Modified factor vii polypeptides for subcutaneous administration

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2916711A1 (de) * 1979-04-25 1980-11-06 Behringwerke Ag Blutgerinnungsfaktoren und verfahren zu ihrer herstellung
US5833982A (en) * 1991-02-28 1998-11-10 Zymogenetics, Inc. Modified factor VII
SE9301581D0 (sv) * 1993-05-07 1993-05-07 Kabi Pharmacia Ab Protein formulation
US5925738A (en) * 1995-12-01 1999-07-20 The American National Red Cross Methods of production and use of liquid formulations of plasma proteins
US5770700A (en) * 1996-01-25 1998-06-23 Genetics Institute, Inc. Liquid factor IX formulations
US20010031721A1 (en) * 1999-05-05 2001-10-18 Chandra Webb Highly concentrated, lyophilized, and liquid factor IX formulations

Also Published As

Publication number Publication date
US20040043933A1 (en) 2004-03-04
IL162618A0 (en) 2005-11-20
JP2005530682A (ja) 2005-10-13
BR0215218A (pt) 2004-11-16
CA2470313A1 (en) 2003-07-10
PL370656A1 (en) 2005-05-30
AU2002351755A1 (en) 2003-07-15
RU2004122430A (ru) 2005-04-20
EP1458407A1 (en) 2004-09-22
WO2003055511A1 (en) 2003-07-10
CN1606452A (zh) 2005-04-13

Similar Documents

Publication Publication Date Title
HUP0402303A2 (hu) Módosított VII-es faktor polipeptidek folyékony készítménye
HUP0402315A2 (hu) VII-es faktor polipeptidek folyékony gyógyszerkészítménye
PL2298287T3 (pl) Stabilizowane kompozycje polipeptydów czynnika VII
EP1478394A4 (en) PREPARATION OF POLYPEPTIDES
AU2003302626A1 (en) 1, 2, 5-thiadiazolidin-3-one 1, 1 dioxide derivatives as inhibitors of protein tyrosine phosphatase ptp1b
AU1870099A (en) Stabilised insulin compositions
ES2099687T1 (es) Cementos de fosfato calcico autofraguables y metodos para prepararlos y usarlos.
AU6473999A (en) Protein material for slow digestion and its use
ATE547114T1 (de) Flüssige zusammensetzungen von factor vii polypeptiden
EA200501675A1 (ru) Фармацевтическая композиция, содержащая лактат, и ее применение
BR9809306A (pt) Inibidores de protease
BR0312521A (pt) Métodos para a separação e a purificação de fibrinogênio e de pelo menos uma outra proteìna e para a co-purificação de fibrinogênio e de fator xiii, uso de cromatografia de afinidade com ìon de metal imobilizado, fibrinogênio, kit farmacêutico, e, formulações farmacêutica e de fibrinogênio liofilizado
IL160171A0 (en) Depsipeptide derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
BR0016547A (pt) Composição para a modulação e inibição da permeabilidade vascular (vp)
WO2003062270A8 (en) Fluorescent protein from aequorea coerulscens and uses therof
MXPA04000428A (es) Alimento que contiene proteina que comprende una enzima de entrelazamiento y un hidrocoloide.
HUP0302441A2 (hu) Antibiotikus hatású gyógyászati készítmények
HUP0400520A2 (hu) Klindamicint és cinksót tartalmazó dermatológiai készítmények
HUP0400976A2 (hu) VII-es faktor polipeptideket és XI-es faktor polipeptideket tartalmazó gyógyszerészeti összetételek
ATE253884T1 (de) Zubereitung zur zahnbehandlung
BR0108562A (pt) Composições endoparasiticidas
HUP0402183A2 (hu) Folyékony élesztőkészítmények
GB0221169D0 (en) Crystal
WO2003002598A3 (en) Peptides for use as translocation factors
PE47599A1 (es) Proteinas antiobesidad